<DOC>
	<DOC>NCT01394770</DOC>
	<brief_summary>Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether aliskiren, a direct renin inhibitor, compared with amlodipine, a calcium channel blocker, reduces mortality and cardiovascular events in these high-risk patients.</brief_summary>
	<brief_title>Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>hemodialysed patients predialytic blood pressure greater or equal to 140/90 mmHg history of heart failure history of ischemic heart disease severe aortic stenosis known allergy to aliskiren or amlodipine severe disorders of liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>hypertension</keyword>
	<keyword>dialysis</keyword>
	<keyword>aliskiren</keyword>
	<keyword>amlodipine</keyword>
	<keyword>outcome</keyword>
</DOC>